• Explore /
  • Poster
  • / Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy.

Phase II open-label, single-center study evaluating safety and efficacy of pembrolizumab following induction with the hypomethylating agent azacitidine in patients with advanced pancreatic cancer after failure of first-line therapy.

Abstract Poster

Authors

null

Rachael A Safyan

Columbia University Medical Center, New York, NY

Rachael A Safyan , Tamas Gonda , Benjamin Tycko , John A. Chabot , Gulam Abbas Manji , Gary K. Schwartz , Paul Eliezer Oberstein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

NCT03264404

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS534)

DOI

10.1200/JCO.2018.36.4_suppl.TPS534

Abstract #

TPS534

Poster Bd #

Q10

Abstract Disclosures

Similar Posters

First Author: Rachael A Safyan

First Author: Jacqueline Vuky

First Author: Yung-Jue Bang

First Author: Lorenza Rimassa